Clinical trials: Active Ulcerative Colitis, open to volunteers
Ulcerative Colitis (UC)
Urinary PGE-MUM as a Marker for Ulcerative Colitis Activity
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that requires regular monitoring of disease activity. Currently, assessment depends on invasive colonoscopy or clinical scores that may not accurately reflect…
- Trial name
- PGE-MUM_UC (NCT07637045)
- Where
- Egypt
- Volunteers
- 114 people
- Sponsor
- Assiut University
Ulcerative Colitis (UC)
Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
The aim of the study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of study drug (BCD-261) in comparison with placebo and to characterize the dose-response relationship in patients…
- Trial name
- ULTRAMARINE (NCT07080034)
- Testing
- anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, high dose
- Where
- 20 sites in Russia
- Volunteers
- 198 people
- Sponsor
- Biocad
Colitis, Ulcerative
Confirmatory Clinical Study in Active Ulcerative Colitis
The main goal of the study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have favorable effects.
- Trial name
- StarFish-UC (NCT07296315)
- Testing
- Low-dose MH002, High-dose MH002
- Where
- 49 sites in United States, Czechia and 5 more
- Volunteers
- 204 people
- Sponsor
- MRM Health NV
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)
Ulcerative colitis is a condition that causes inflammation and ulcers in the large intestine. MGT-006 is an investigational oral capsule containing viable gut microbiota from screened human donors.
- Trial name
- ROOT (NCT07913347)
- Testing
- MGT-006, Vancomycin hydrochloride, Amoxicillin hydrate/ Fosfomycin calcium hydrate/ Metronidazole
- Where
- 12 sites in United States, Japan
- Volunteers
- 54 people
- Sponsor
- Metagen Therapeutics, Inc.
Ulcerative Colitis
Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis.
This study aims to evaluate the efficacy and safety of acupuncture combined with mesalazine (an integrated acupuncture-medication regimen) for ulcerative colitis.
- Trial name
- NCT07389824
- Testing
- Acupuncture, Mesalazine
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Qin Yu
Ulcerative Colitis, Inflammatory Bowel Diseases
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
- Trial name
- SKYLINE-UC (NCT07012395)
- Testing
- SPY001, SPY002, SPY003
- Where
- 276 sites in United States, Argentina and 33 more
- Volunteers
- 645 people
- Sponsor
- Spyre Therapeutics, Inc.
Ulcerative Colitis (UC)
Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
The purpose of this phase III, multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of Hemay005 compared to placebo as induction and maintenance therapy in Chinese participants with…
- Trial name
- NCT07650942
- Testing
- Hemay005 tablet
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Ulcerative Colitis, Unspecified
Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis
Double-blind, randomised, placebo-controlled phase II / III trial evaluating efficacy and safety of two different doses (2 g/d or 3 g/d) of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) compared to placebo in…
- Trial name
- NCT06488625
- Testing
- Low-Dose CICR-NAM, High-Dose CICR-NAM, 0 g/d CICR-NAM (blinded)
- Where
- 25 sites in Germany
- Volunteers
- 459 people
- Sponsor
- University Hospital Schleswig-Holstein
Ulcerative Colitis
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- TOPAZ-UC (NCT07186101)
- Testing
- LY4268989, Mirikizumab
- Where
- 147 sites in United States, Austria and 15 more
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- NCT06764706
- Where
- 57 sites in Germany
- Volunteers
- 200 people
- Sponsor
- AbbVie
Ulcerative Colitis (UC)
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PTT-621 in Patients With Moderately to Severely Active Ulcerative Colitis
This Phase IIa, multicenter, single-arm trial evaluates the efficacy, safety, tolerability, and pharmacokinetics of PTT-621 tablets in adults (18-70 years) with moderate-to-severe active ulcerative colitis (UC) who have…
- Trial name
- NCT07747155
- Testing
- PTT-621 Tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Pyrotech Therapeutics, Inc.
Crohn's Disease, Ulcerative Colitis
Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD) represent a group of immune-mediated disorders, in which currently unidentified trigger factors drive the manifestation of chronic relapsing- remitting destructive inflammatory episodes in the…
- Trial name
- 3TR (NCT05733845)
- Testing
- Samples
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Ulcerative Colitis
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- MIGHTY (NCT07071519)
- Testing
- Risankizumab
- Where
- 73 sites in United States, Belgium and 14 more
- Volunteers
- 120 people
- Sponsor
- AbbVie
Ulcerative Colitis
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
The aim of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of filgotinib as a treatment for UC in children and adolescents aged from 8 to less than 18 years.
- Trial name
- Galapeduca (NCT06865417)
- Testing
- Filgotinib
- Where
- 46 sites in Belgium, Croatia and 11 more
- Volunteers
- 80 people
- Sponsor
- Alfasigma S.p.A.
IBD (Inflammatory Bowel Disease)
E-nose in Evaluating Colitis Activity
The goal of this observational study is to learn whether a rapid stool-based imaging test can help monitor inflammatory bowel disease (IBD) in children.
- Trial name
- SPECTROS (NCT07781215)
- Testing
- Differential Mobile Spectrometry analysis of the stool
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Tampere University Hospital
Inflammatory Bowel Diseases, Crohn Disease (CD)
Early Inflammatory Bowel Disease Progression
The purpose of this study is to assess the capacity of the gut microbial composition and function to predict the course of IBD during the first year after diagnosis.
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- PRO-IBD (NCT06756100)
- Where
- Chile
- Volunteers
- 140 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Ulcerative Colitis (UC)
Palmitoylethanolamide in Ulcerative Colitis
Evaluate the effects of PEA supplementation on disease activity, health-related quality of life (HRQoL) and inflammatory biomarkers in patients with active mild-to-moderate UC.
- Trial name
- NCT07609810
- Testing
- Palmitoylethanolamide (PEA)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Adult Patients With Moderately to Severely Active Ulcerative Colitis
A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial comprising screening period, treatment period, and follow-up period.
- Trial name
- NCT07229950
- Testing
- HRS-7085
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Ulcerative Colitis (UC)
A Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ENC1018 Capsules in Patients With Moderate-to-severe Active Ulcerative Colitis (UC)
This is an open-label, single-arm, single-center study to evaluate the safety, pharmacokinetics, and efficacy signal of ENC1018 capsules in patients with moderate-to-severe active ulcerative colitis (UC).
- Trial name
- NCT07062185
- Testing
- ENC1018 capsule administration group
- Volunteers
- 10 people
- Sponsor
- Tang-Du Hospital
Ulcerative Colitis, Crohn's Disease
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin…
- Trial name
- NCT06100289
- Testing
- Vedolizumab IV, Vedolizumab SC
- Where
- 54 sites in United States, Belgium and 14 more
- Volunteers
- 70 people
- Sponsor
- Takeda